HealthEquity (HQY)
(Delayed Data from NSDQ)
$79.87 USD
-0.40 (-0.50%)
Updated Apr 17, 2024 04:00 PM ET
After-Market: $79.87 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth D Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
HQY 79.87 -0.40(-0.50%)
Will HQY be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for HQY based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for HQY
Why HealthEquity (HQY) is a Top Growth Stock for the Long-Term
Why HealthEquity (HQY) is a Top Growth Stock for the Long-Term
HQY: What are Zacks experts saying now?
Zacks Private Portfolio Services
HealthEquity (HQY) Q4 Earnings Surpass Estimates, Margins Up
Compared to Estimates, HealthEquity (HQY) Q4 Earnings: A Look at Key Metrics
HealthEquity (HQY) Beats Q4 Earnings and Revenue Estimates
Other News for HQY
Analysts Offer Insights on Healthcare Companies: Edgewise Therapeutics (EWTX), Healthequity (HQY) and Nuvation Bio (NUVB)
HealthEquity Expands Portfolio with Conduent Acquisition
HealthEquity (HQY): Assessing Its Market Valuation
TipRanks’ ‘Perfect 10’ List: Analysts Throw Weight Behind These 2 Top-Scoring Stocks
JMP starts HealthEquity at market outperform, cites revenue growth